 This was a 16-week, randomized, double-blind study for comparing metformin plus mitiglinide MetMit versus metformin plus placebo MetPcb. An 8-week metformin run-in phase 500 mg twice a day for the first 4 weeks and 500 mg three times a day for the following 4 weeks was followed by a 16-week trial phase mitiglinide 10 mg or placebo three times a day added to metformin 500 mg three times a day. The subjects with an HbA1c 7.0 at the end of the metformin run-in phase were randomized to a MetMit group or a MetPcb group of the trial phase. 